Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

Razer is offering players a chance to get their hands on Battlefield 6 early access codes. The official Razer social pages ...

The Assault class is the frontline segment. They are responsible for pushing through enemy defenses using some of the most ...

Eric Wrona aka Snip3down is one of the most DEDICATED gamers in the world! Watch Snip3down & TSM in the ALGS Championship ...

Reports Q2 revenue $965,000, consensus $433,330. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory ...

The latest Apex Legends patch changes Caustic and Bangalore ahead of Season 26: Showdown, impacting the casual and esports ...

Apex Legends is finally coming to the Nintendo Switch 2 and will offer an exclusive Legendary Pathfinder skin for free.

Learn about the executive team and board of directors at Aligos Therapeutics Inc Ordinary Shares (ALGS:XNAS) and review their bios and compensation over the latest fiscal years.

Find annual and quearterly earnings data for Aligos Therapeutics, Inc. Common Stock (ALGS) including earnings per share, earnings forecasts at Nasdaq.com.

The Gaimin Gladiators organization has ended its cooperation with the Apex Legends roster, as reported on the eSports club's social networks.